Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 67 citing articles:

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
Dario Giugliano, Miriam Longo, Simona Signoriello, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 98
Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin
Rosalba La Grotta, Paola de Candia, Fabiola Olivieri, et al.
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 5
Open Access | Times Cited: 81
Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
David M. Williams, Hannah Jones, Jeffrey W. Stephens
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 281-295
Open Access | Times Cited: 77
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
Arturo Cesaro, Felice Gragnano, Pasquale Paolisso, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 62
SGLT2 Inhibitors and Their Antiarrhythmic Properties
Ewald Kolesnik, Douglas S. Scherr, Ursula Rohrer, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1678-1678
Open Access | Times Cited: 42
Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
Rosalba La Grotta, Chiara Frigé, Giulia Matacchione, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12325-12325
Open Access | Times Cited: 38
The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes
Antonio Ceriello, Giuseppe Lucisano, Francesco Prattichizzo, et al.
The Lancet Regional Health - Europe (2023) Vol. 31, pp. 100666-100666
Open Access | Times Cited: 22
Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
Ruining Zhang, Qingxing Xie, Xi Lu, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 10
2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care
Samuel Seidu, Xavier Cos, Stephen Brunton, et al.
Primary care diabetes (2022) Vol. 16, Iss. 2, pp. 223-244
Open Access | Times Cited: 31
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
André Scheen
Drugs (2024)
Closed Access | Times Cited: 7
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease
Riccardo Nevola, Maria Rosaria Alfano, Pia Clara Pafundi, et al.
Reviews in Cardiovascular Medicine (2022) Vol. 23, Iss. 3
Open Access | Times Cited: 25
Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
Thahesh Tharmaraja, Jamie Sin Ying Ho, Ching‐Hui Sia, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13, pp. 204062232210869-204062232210869
Open Access | Times Cited: 24
Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium‐glucose cotransporter‐2 inhibitors versus other medications: A systematic review and meta‐analysis of observational cohort studies
Anna Hodgson, Clare Gillies, Patrick Highton, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2487-2491
Open Access | Times Cited: 5
Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
Yihai Liu, Mingyue Wu, Biao Xu, et al.
Journal of Inflammation Research (2021) Vol. Volume 14, pp. 2277-2287
Open Access | Times Cited: 30
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André Scheen
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101474-101474
Closed Access | Times Cited: 11
Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials
Wenjing Xia, Hua Yu, Lei Xia, et al.
Medicine (2024) Vol. 103, Iss. 11, pp. e37432-e37432
Open Access | Times Cited: 4
Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis
Xiaoyan Liang, Jianghong Dai, Feifei Wang
BMC Cardiovascular Disorders (2025) Vol. 25, Iss. 1
Open Access
Implications of Heart Failure Treatment on Atrial Fibrillation Onset: A Retrospective Study
Loredana Suhov, Adrian Apostol, Larissa Dăniluc, et al.
Medicina (2025) Vol. 61, Iss. 3, pp. 414-414
Open Access
Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation
Merita Rroji, Nereida Spahia, Andreja Figurek, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 728-728
Open Access
The Efficacy and Safety of SGLT2 Inhibitors in Diabetes Kidney Transplant Recipients: A Systematic Review and Meta-Analysis
Kanachai Boonpiraks, Pajaree Krisanapan, Suthiya Anumas, et al.
F1000Research (2025) Vol. 14, pp. 329-329
Open Access
Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
Chun Xing Li, Tian Tian Liu, Qian Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry
Xinyu Li, Rudolf T. Hoogenveen, Mohamed El Alili, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 10, pp. 1249-1262
Open Access | Times Cited: 8
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
André Scheen
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1053-1062
Closed Access | Times Cited: 8
Cardiovascular Disease Prevention and Therapy in Women With Type 2 Diabetes
Camilla Cocchi, Francesca Coppi, Alberto Farinetti, et al.
Future Cardiology (2021) Vol. 17, Iss. 3, pp. 487-496
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top